Tag: Arbutus Biopharma Corp


Arbutus Biopharma Corp (NASDAQ: ABUS) Displays New Particulars on AB-729 and AB-836 Lineups

Arbutus Biopharma Corp (NASDAQ: ABUS) today announced the demonstration of five summaries at the European Association for the Study of the Liver (EASL) International Liver CongressTM (ILC).  Summaries presented by Professor Man-Fung Yuen The synopses encompassed an oral late-breaker validation (Demonstration LBO-2764) by Professor Man-Fung Yuen, D.Sc., M.D., Ph.D., and […]